Extraneal Icodextrin Peritoneal Dialysis Solution

1. Indications and Usage
ESRD: Icodextrin Peritoneal Dialysis Solution is indicated for the treatment of patients with end-stage renal disease (ESRD).
PD Modality: It is used for a single daily long dwell (8 to 16 hours) in continuous ambulatory peritoneal dialysis (CAPD).
Target Population: It is indicated to improve long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high or high-average peritoneal membrane transport status, as diagnosed by peritoneal equilibration test (PET).
2. Dosage and Administration
ROUTE: For intraperitoneal use only. It is not indicated for intravenous or intra-arterial administration.
Frequency: It is administered as a single daily exchange during CAPD.
Dwell Time: The recommended dwell time is 8 to 16 hours.
Administration: The solution should be infused into the peritoneal cavity at a rate comfortable for the patient, typically within 10 to 20 minutes.
3. Mechanism of Action
Osmotic Agent: Icodextrin is a glucose polymer that generates a sustained colloid osmotic pressure.
Ultrafiltration: This osmotic gradient facilitates the removal of excess fluid from the blood over the extended dwell period, overcoming the absorption limitations associated with free glucose.
Toxin Clearance: By maintaining ultrafiltration, it ensures effective clearance of low molecular weight solutes such as creatinine and urea.
4. Safety and Warnings
Hypoglycemia Risk: Icodextrin is metabolized to maltose, which can interfere with glucose monitoring systems.
Glucose Monitoring: Patients must use glucose monitoring systems that employ glucose dehydrogenase pyrloquinoline quinone (GDH-PQQ) or glucose oxidase to avoid false hyperglycemia readings that may lead to inappropriate insulin administration.
Lactic Acidosis: In patients with severe renal impairment, the accumulation of metabolites may rarely lead to lactic acidosis.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include abdominal pain, peritonitis, catheter-related infections, and electrolyte imbalances.
Clinical Research: Clinical trials have demonstrated that icodextrin-based dialysis significantly improves ultrafiltration volume and solute clearance compared to high-concentration glucose solutions in long-dwell exchanges.
6. Drug Interactions
Glucose Monitoring Systems: Concomitant use with certain glucose monitoring systems may result in falsely elevated blood glucose readings.
Nephrotoxic Agents: Concomitant use with nephrotoxic drugs may exacerbate renal impairment, potentially altering the metabolism and clearance of icodextrin and its metabolites.
7. Pharmaceutical Information
Composition: The solution contains 7.5% icodextrin in an electrolyte solution with 40 mEq/L lactate.
Appearance: It is a clear, colorless, and sterile solution.
Storage: Store at controlled room temperature. Do not freeze or use if the solution is discolored or contains particulate matter.